Interventions for age-related diseases: Shifting the paradigm.
Over 60% of people aged over 65 are affected by multiple morbidities, which are more difficult to treat, generate increased healthcare costs and lead to poor quality of life compared to individual diseases. With the number of older people steadily increasing this presents a societal challenge. Age is the major risk factor for age-related diseases and recent research developments have led to the proposal that pharmacological interventions targeting common mechanisms of ageing may be able to delay the onset of multimorbidity. Here we review the state of the knowledge of multimorbidity, appraise the available evidence supporting the role of mechanisms of ageing in the development of the most common age-related diseases and assess potential molecules that may successfully target those key mechanisms.
Instituto de Tecnologia Química e Biológica António Xavier, Universidade Nova de Lisboa, Oeiras, Portugal; iBET, Instituto de Biologia Experimental e Tecnológica, Oeiras, Portugal.
Inês
I
Figueira
Research Institute for Medicines - iMed.ULisboa, Faculdade de Farmácia, Universidade de Lisboa, Lisboa, Portugal; Department of Biochemistry and Human Biology, Faculdade de Farmácia, Universidade de Lisboa, Lisboa, Portugal.
Adelaide
A
Fernandes
Institute for Biological Research "Sinisa Stankovic", University of Belgrade, Blvd. Despota Stefana, 142, 11000 Belgrade, Serbia.
Aleksandra
A
Mladenovic Djordjevic
Center for Chromosome Stability, Department of Cellular and Molecular Medicine, Panum Institute, University of Copenhagen, 2200 Copenhagen N, Denmark.
Andres
A
Lopez-Contreras
Department of Oncology & Metabolism, The University of Sheffield, The Medical School, Sheffield, UK.
Catarina M
CM
Henriques
Glasgow Ageing Research Network (GARNER), Institute of Biodiversity, Animal Health and Comparative Medicine, University of Glasgow, Glasgow, UK.
Colin
C
Selman
Center for Neuroscience and Cell Biology, University of Coimbra, Coimbra, Portugal.
Elisabete
E
Ferreiro
National Helenic Research Foundation, Institute of Biology, Medicinal Chemistry and Biotechnology, Athens, Greece.
Efstathios S
ES
Gonos
Department of Molecular, Cellular and Developmental Neuroscience, Cajal Institute - CSIC, Madrid, Spain.
José Luis
JL
Trejo
MRC Arthiritis Research UK Centre for Integrated Research into Musculoskeletal Ageing (CIMA), Department of Oncology and Metabolism, University of Sheffield, The Medical School, Sheffield, UK.
Juhi
J
Misra
Center for Healthy Ageing, Department of Cellular and Molecular Medicine, University of Copenhagen, 2200 Copenhagen N, Denmark.
Lene Juel
LJ
Rasmussen
Instituto de Farmacologia e Neurociências, Faculdade de Medicina, Universidade de Lisboa, Lisboa, Portugal; Instituto de Medicina Molecular, Faculdade de Medicina, Universidade de Lisboa, Lisboa, Portugal.
Sara
S
Xapelli
Department of Cardiovascular Science, Sheffield University, Medical School, Beech Hill Road, Sheffield S10 2RX, UK; Sheffield Kidney Institute, Northern General Hospital, Herries Road, Sheffield S5 7AU, UK.
Timothy
T
Ellam
MRC Arthiritis Research UK Centre for Integrated Research into Musculoskeletal Ageing (CIMA), Department of Oncology and Metabolism, University of Sheffield, The Medical School, Sheffield, UK. Electronic address: i.bellantuono@sheffield.ac.uk.
Ilaria
I
Bellantuono
D000368:Aged; D000369:Aged, 80 and over; D000375:Aging / Q000235:genetics* / Q000378:metabolism* / Q000473:pathology*; D006801:Humans
Ageing; Chronic diseases; Geroprotectors; Geroscience; Multimorbidity